Found 206 cc-cancer-center trials
A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
The purpose of this study is to evaluate how well the study drug (Navitoclax) works in combination with ruxolitinib when compared to best available therapy in subjects with Relapsed/Refractory Myelofibrosis.
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV-101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The diseases under study include: idiopathic necrotizing myopathy (INM) consisting of dermatomyositis (DM), necrotizing myopathy, anti-HMGCoA-associated myopathy, and polymyositis (PM), …
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.
The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study …
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
